Art

J-GLOBAL ID：202002284415057157   Reference number：20A0582234

Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study

進行性ALK再配列非小細胞肺癌患者におけるセリチニブ+ニボルマブ: オープンラベル,多施設,第1相試験の結果【JST・京大機械翻訳】

Author (18)： Felip Enriqueta (Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain) ,  de Braud Filippo G. (University of Milan, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy) ,  Maur Michela (AOU Policlinico of Modena, University of Modena and Reggio Emilia, Modena, Italy) ,  Loong Herbert H. (The Chinese University of Hong Kong, Hong Kong Special Administrative Region, People’s Republic of China) ,  Shaw Alice Tsang (Massachusetts General Hospital, Boston, Massachusetts) ,  Vansteenkiste Johan F. (University Hospital KU Leuven, Leuven, Belgium) ,  John Thomas (Austin Health, Melbourne, Australia) ,  Liu Geoffrey (Princess Margaret Cancer Centre, Toronto, Ontario, Canada) ,  Lolkema Martijn P. (Erasmus MC Cancer Institute, Rotterdam, The Netherlands) ,  Selvaggi Giovanni (Bristol-Myers Squibb, Princeton, New Jersey) ,  Giannone Vanessa (Novartis Pharmaceuticals Corporation, East Hanover, New Jersey) ,  Cazorla Pilar (Novartis Pharmaceuticals Corporation, East Hanover, New Jersey) ,  Baum Jason (Novartis Institutes for Biomedical Research, Cambridge, Massachusetts) ,  Balbin O. Alejandro (Novartis Institutes for Biomedical Research, Cambridge, Massachusetts) ,  Wang Luojun (Victor) (Novartis Pharmaceuticals Corporation, East Hanover, New Jersey) ,  Lau Yvonne Y. (Novartis Pharmaceuticals Corporation, East Hanover, New Jersey) ,  Scott Jeffrey W. (Novartis Pharmaceuticals Corporation, East Hanover, New Jersey) ,  Tan Daniel Shao-Weng (National Cancer Centre Singapore, Singapore)
Material： Journal of Thoracic Oncology
Volume： 15  Issue： 3  Page： 392-403  Publication year： 2020 
JST Material Number： W3145A  ISSN： 1556-0864  Document type： Article
Article type： 原著論文  Country of issue： Netherlands (NLD)  Language： ENGLISH (EN)

Abstract/Point： Induction of programmed death ...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=20A0582234&from=J-GLOBAL&jstjournalNo=W3145A") }}

Thesaurus term： estimator ,  drug therapy ,  lipase ,  population(statistics) ,  gene ,  ash content ,  death ,  receptor tyrosine kinase ,  dyeing ,  *phase 1 study ,  carcinogenicity ,  phase(topology) ,  reorganization ,  percent conversion ,  *non-small cell lung cancer

Author keywords (5)： Ceritinib ,  Nivolumab ,  ALK ,  PD-1 ,  NSCLC

JST classification (3)： Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Clinical application of antitumor(=antineoplastic)drugs  (GW16020L) ,  Tumors(=neoplasms)of respiratory system  (GI04000G)

Terms in the title (9)： ALK ,  再配列 ,  非小細胞肺癌 ,  患者 ,  セリチニブ ,  ニボルマブ ,  ラベル ,  施設 ,  第1相試験